keyword
MENU ▼
Read by QxMD icon Read
search

dementia imaging

keyword
https://www.readbyqxmd.com/read/29453244/white-matter-change-with-apathy-and-impulsivity-in-frontotemporal-lobar-degeneration-syndromes
#1
Claire J Lansdall, Ian T S Coyle-Gilchrist, P Simon Jones, Patricia Vázquez Rodríguez, Alicia Wilcox, Eileen Wehmann, Katrina M Dick, Trevor W Robbins, James B Rowe
OBJECTIVE: To identify the white matter correlates of apathy and impulsivity in the major syndromes associated with frontotemporal lobar degeneration, using diffusion-weighted imaging and data from the PiPPIN (Pick's Disease and Progressive Supranuclear Palsy: Prevalence and Incidence) study. We included behavioral and language variants of frontotemporal dementia, corticobasal syndrome, and progressive supranuclear palsy. METHODS: Seventy patients and 30 controls underwent diffusion tensor imaging at 3-tesla after detailed assessment of apathy and impulsivity...
February 16, 2018: Neurology
https://www.readbyqxmd.com/read/29453242/single-subject-spm-fdg-pet-patterns-predict-risk-of-dementia-progression-in-parkinson-disease
#2
Andrea Pilotto, Enrico Premi, Silvia Paola Caminiti, Luca Presotto, Rosanna Turrone, Antonella Alberici, Barbara Paghera, Barbara Borroni, Alessandro Padovani, Daniela Perani
OBJECTIVE: To evaluate the statistical parametric mapping (SPM) procedure for fluorodeoxyglucose (FDG)-PET imaging as a possible single-subject marker of progression to dementia in Parkinson disease (PD). METHODS: Fifty-four consecutive patients with PD without dementia (age at onset of 59.9 ± 10.1 years, disease duration of 5.3 ± 3.4 years) entered the study. The patients underwent an extensive motor and cognitive assessment and a single-subject FDG-PET SPM evaluation at baseline...
February 16, 2018: Neurology
https://www.readbyqxmd.com/read/29441485/clinical-spectrum-of-c9orf72-expansion-in-a-cohort-of-huntington-s-disease-phenocopies
#3
Joana Martins, Joana Damásio, Alexandre Mendes, Nuno Vila-Chã, José E Alves, Cristina Ramos, Sara Cavaco, João Silva, Isabel Alonso, Marina Magalhães
The expansion in the C9orf72 gene has been recently reported as a genetic cause of Huntington's disease (HD) phenocopies. We aim to assess the frequency of the C9orf72 gene expansion in a Portuguese HD phenocopies cohort. Twenty HD phenotype-like patients without diagnosis were identified in our institutional database. C9orf72 gene expansion was detected using repeat-primed PCR. Clinical files were reviewed to characterize the phenotype of expansion-positive cases. One patient (5%) was positive for the C9orf72 expansion...
February 13, 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29439322/cerebrospinal-fluid-biomarkers-are-differentially-related-to-structural-and-functional-changes-in-dementia-of-the-alzheimer-s-type
#4
Charles B Malpas, Michael M Saling, Dennis Velakoulis, Patricia Desmond, Rodney J Hicks, Henrik Zetterberg, Kaj Blennow, Terence J O'Brien
The two cardinal pathologies of Alzheimer's disease (AD) develop according to distinct anatomical trajectories. Cerebral tau-related pathology first accumulates in the mesial temporal region, while amyloid-related pathology first appears in neocortex. The eventual distributions of these pathologies reflect their anatomical origins. An implication is that the cardinal pathologies might exert preferential effects on the structurofunctional brain changes observed in AD. We investigated this hypothesis in 39 patients with dementia of the Alzheimer's type...
2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29438037/tau-negative-amnestic-dementia-masquerading-as-alzheimer-disease-dementia
#5
Hugo Botha, William G Mantyh, Jonathan Graff-Radford, Mary M Machulda, Scott A Przybelski, Heather J Wiste, Matthew L Senjem, Joseph E Parisi, Ronald C Petersen, Melissa E Murray, Bradley F Boeve, Val J Lowe, David S Knopman, Clifford R Jack, David T Jones
OBJECTIVE: To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research. METHODS: Eight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging...
February 7, 2018: Neurology
https://www.readbyqxmd.com/read/29435558/association-between-amyloid-and-tau-accumulation-in-young-adults-with-autosomal-dominant-alzheimer-disease
#6
Yakeel T Quiroz, Reisa A Sperling, Daniel J Norton, Ana Baena, Joseph F Arboleda-Velasquez, Danielle Cosio, Aaron Schultz, Molly Lapoint, Edmarie Guzman-Velez, John B Miller, Leo A Kim, Kewei Chen, Pierre N Tariot, Francisco Lopera, Eric M Reiman, Keith A Johnson
Importance: It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms. Objective: To characterize the associations between amyloid and tau deposits in the brains of cognitively unimpaired and impaired carriers of presenilin 1 (PSEN1) E280A mutation...
February 12, 2018: JAMA Neurology
https://www.readbyqxmd.com/read/29433115/-new-diagnostic-criteria-for-parkinson-s-disease-mds-pd-criteria
#7
Hirohisa Watanabe, Kazuhiro Hara, Mizuki Ito, Masahisa Katsuno, Gen Sobue
The International Parkinson and Movement Disorder Society offered standard diagnostic criteria for Parkinson's disease (PD) in 2015. These diagnostic criteria provided systematization of the diagnostic process and detailed explanations of parkinsonism, absolute exclusion criteria, red flags, and supportive criteria. The presence of parkinsonism was a core feature of the criteria. Clear instructions for defining the motor features were described. With regard to the novel aspects, non-motor manifestations (hyposmia, autonomic dysfunction, psychiatric dysfunction, and sleep dysfunction) and ancillary diagnostic tests (olfactory test, cardiac MIBG scintigraphy, and presynaptic dopaminergic imaging) were incorporated...
February 2018: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/29432610/accelerometer-physical-activity-is-associated-with-greater-gray-matter-volumes-in-older-adults-without-dementia-or-mild-cognitive-impairment
#8
Shannon Halloway, Konstantinos Arfanakis, JoEllen Wilbur, Michael E Schoeny, Susan J Pressler
Objectives: Physical activity (PA) is a modifiable health behavior that can protect against age-related gray matter atrophy and cognitive dysfunction. Current studies of PA and gray matter failed to utilize device measures of PA and do not focus on adults >80 years. Thus, the purpose of this secondary analysis was to examine cross-sectional associations between accelerometer lifestyle PA and (a) gray matter volumes and (b) cognitive function, controlling for demographics and health status...
February 8, 2018: Journals of Gerontology. Series B, Psychological Sciences and Social Sciences
https://www.readbyqxmd.com/read/29432519/the-role-of-biomarkers-and-imaging-in-the-clinical-diagnosis-of-dementia
#9
Antony J Bayer
Recognition of dementia relies on a good clinical history, supported by formal cognitive testing, but identifying the subtype of dementia may be wrong in 20% or more of cases. Accuracy may be improved by use of imaging and cerebrospinal fluid (CSF) biomarkers. Structural neuroimaging is recommended for most patients, not just to identify potentially reversible surgical pathology, but also to detect vascular changes and patterns of cerebral atrophy. Functional imaging can help to confirm neurodegeneration and to distinguish dementia subtypes when structural imaging has been inconclusive...
February 8, 2018: Age and Ageing
https://www.readbyqxmd.com/read/29429985/posterior-associative-and-cingulate-cortex-involvement-of-brain-single-photon-emission-computed-tomography-spect-imaging-in-semantic-dementia-with-probable-alzheimer-disease-pathology-a-case-report
#10
Yumi Takano, Keiko Kunitoki, Yasuko Tatewaki, Tatsushi Mutoh, Tomoko Totsune, Hideo Shimomura, Manabu Nakagawa, Hiroyuki Arai, Yasuyuki Taki
BACKGROUND Semantic dementia (SD) is a type of primary progressive aphasia with prominent language dysfunction, mostly within the spectrum of frontotemporal lobar degeneration (FTLD). Although there is an overlap in clinical manifestations of SD attributable to FTLD and neuropathologically proven Alzheimer disease (AD), clinical diagnostic clues are not readily available. We present a characteristic finding based on a single-photon emission computed tomography (SPECT)-based regional cerebral blood flow study and its statistical imaging analysis for a rare case of SD with AD-like pathology...
February 12, 2018: American Journal of Case Reports
https://www.readbyqxmd.com/read/29423814/connectivity-based-characterisation-of-subcortical-grey-matter-pathology-in-frontotemporal-dementia-and-als-a-multimodal-neuroimaging-study
#11
Peter Bede, Taha Omer, Eoin Finegan, Rangariroyashe H Chipika, Parameswaran M Iyer, Mark A Doherty, Alice Vajda, Niall Pender, Russell L McLaughlin, Siobhan Hutchinson, Orla Hardiman
Frontotemporal dementia (FTD) phenotypes have distinctive and well-established cortical signatures, but their subcortical grey matter profiles are poorly characterised. The comprehensive characterisation of striatal and thalamic pathology along the ALS-FTD spectrum is particularly timely, as dysfunction of frontostriatal and cortico-thalamic networks contribute to phenotype-defining cognitive, behavioral, and motor deficits. Ten patients with behavioral-variant FTD, 11 patients with non-fluent-variant primary progressive aphasia, 5 patients with semantic-variant primary progressive aphasia, 14 ALS-FTD patients with C9orf72 hexanucleotide expansions, 12 ALS-FTD patients without hexanucleotide repeats, 36 ALS patients without cognitive impairment and 50 healthy controls were included in a prospective neuroimaging study...
February 8, 2018: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/29419659/validation-of-prognostic-biomarker-scores-for-predicting-progression-of-dementia-in-patients-with-amnestic-mild-cognitive-impairment
#12
Jamie Moreland, Timo Urhemaa, Mark van Gils, Jyrki Lötjönen, Jan Wolber, Christopher J Buckley
OBJECTIVE: The objective of this study was to develop and validate a practical computerized prognostic model that uses baseline psychometric and imaging data, including results of PET imaging of amyloid deposition, to predict the progression to dementia in patients at risk for Alzheimer's disease (AD). PATIENTS AND METHODS: Data from patients in a phase II trial of [F]flutemetamol for PET imaging of brain amyloid and from the Alzheimer's Disease Neuroimaging Initiative were used to train the prognostic model to yield a disease state index (DSI), a measure of the similarity of an individual patient's data to data from patients in specific diagnostic groups...
February 6, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29415768/design-and-first-baseline-data-of-the-dzne-multicenter-observational-study-on-predementia-alzheimer-s-disease-delcode
#13
Frank Jessen, Annika Spottke, Henning Boecker, Frederic Brosseron, Katharina Buerger, Cihan Catak, Klaus Fliessbach, Christiana Franke, Manuel Fuentes, Michael T Heneka, Daniel Janowitz, Ingo Kilimann, Christoph Laske, Felix Menne, Peter Nestor, Oliver Peters, Josef Priller, Verena Pross, Alfredo Ramirez, Anja Schneider, Oliver Speck, Eike Jakob Spruth, Stefan Teipel, Ruth Vukovich, Christine Westerteicher, Jens Wiltfang, Steffen Wolfsgruber, Michael Wagner, Emrah Düzel
BACKGROUND: Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer's disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decline (SCD) is a pre-mild cognitive impairment (pre-MCI) at-risk state of dementia, which emerges as a highly promising target for AD prevention. METHODS: The German Center for Neurodegenerative Diseases (DZNE) is conducting the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE), which focuses on the characterization of SCD in patients recruited from memory clinics...
February 7, 2018: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/29413519/imaging-translocator-protein-as-a-biomarker-of-neuroinflammation-in-dementia
#14
William C Kreisl, Ioline D Henter, Robert B Innis
Neuroinflammation has long been considered a potential contributor to neurodegenerative disorders that result in dementia. Accumulation of abnormal protein aggregates in Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies is associated with the activation of microglia and astrocytes into proinflammatory states, and chronic low-level activation of glial cells likely contributes to the pathological changes observed in these and other neurodegenerative diseases. The 18kDa translocator protein (TSPO) is a key biomarker for measuring inflammation in the brain via positron emission tomography (PET)...
2018: Advances in Pharmacology
https://www.readbyqxmd.com/read/29410622/serum-hepatocyte-growth-factor-is-associated-with-small-vessel-disease-in-alzheimer-s-dementia
#15
Yanan Zhu, Saima Hilal, Yuek L Chai, M K Ikram, Narayanaswamy Venketasubramanian, Christopher P Chen, Mitchell K P Lai
Background: While hepatocyte growth factor (HGF) is known to exert cell growth, migration and morphogenic effects in various organs, recent studies suggest that HGF may also play a role in synaptic maintenance and cerebrovascular integrity. Although increased levels of HGF have been reported in brain and cerebrospinal fluid (CSF) samples of patients with Alzheimer's disease (AD), it is unclear whether peripheral HGF may be associated with cerebrovascular disease (CeVD) and dementia. In this study, we examined the association of baseline serum HGF with neuroimaging markers of CeVD in a cohort of pre-dementia (cognitive impaired no dementia, CIND) and AD patients...
2018: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29406924/white-matter-hyperintensities-on-mri-in-dementia-with-lewy-bodies-parkinson-s-disease-with-dementia-and-alzheimer-s-disease
#16
Hideto Joki, Yuichi Higashiyama, Yoshiharu Nakae, Chiharu Kugimoto, Hiroshi Doi, Katsuo Kimura, Hitaru Kishida, Naohisa Ueda, Tatsu Nakano, Tatsuya Takahashi, Shigeru Koyano, Hideyuki Takeuchi, Fumiaki Tanaka
BACKGROUND: In dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), it is still debated whether white matter hyperintensities (WMH) on MRI reflect atherosclerotic cerebrovascular changes or Alzheimer's disease (AD)-related pathology such as cerebral amyloid angiopathy. To examine AD-related pathology in DLB and PDD, we compared the severity of WMH and medial temporal lobe atrophy among patients with DLB, PDD, non-demented PD (PDND), and AD. METHODS: We retrospectively studied sex- and age-matched outpatients with AD, DLB, PDD, and PDND, as well as subjects without central nervous system disorders as normal controls (n=50 each)...
February 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29406901/scan-without-evidence-of-dopaminergic-deficit-swedd-in-degenerative-parkinsonism-and-dementia-with-lewy-bodies-a-prospective-study
#17
Nicolas Nicastro, Pierre R Burkhard, Valentina Garibotto
BACKGROUND: 123I-FP-CIT SPECT imaging is a reliable method to assess presynaptic dopaminergic pathways in degenerative parkinsonisms and dementia with Lewy bodies (DLB). METHODS: We aimed at examining sensitivity of combined visual and semi-quantitative 123I-FP-CIT SPECT analyses in a prospective cohort of subjects with DLB and degenerative parkinsonisms - Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) to determine prevalence and clinical significance of scans without evidence of dopaminergic deficit (SWEDD)...
February 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29405229/effects-of-omega-3-fatty-acids-on-resting-cerebral-perfusion-in-patients-with-mild-cognitive-impairment-a-randomized-controlled-trial
#18
C Schwarz, M Wirth, L Gerischer, U Grittner, A V Witte, T Köbe, A Flöel
Alteration of cerebral perfusion can be considered as a possible therapeutic target in mild cognitive impairment. This randomized, placebo-controlled, double-blind proof-of-concept study assessed effects of omega-3 fatty acids on cerebral perfusion in patients with mild cognitive impairment. In thirteen patients (omega:n=5; placebo:n=8) cerebral perfusion was measured before and after 26-weeks intervention within posterior cortical regions using magnetic resonance imaging. There was a medium effect of intervention on cerebral blood flow (η2=0...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29400711/pericyte-degeneration-causes-white-matter-dysfunction-in-the-mouse-central-nervous-system
#19
Axel Montagne, Angeliki M Nikolakopoulou, Zhen Zhao, Abhay P Sagare, Gabriel Si, Divna Lazic, Samuel R Barnes, Madelaine Daianu, Anita Ramanathan, Ariel Go, Erica J Lawson, Yaoming Wang, William J Mack, Paul M Thompson, Julie A Schneider, Jobin Varkey, Ralf Langen, Eric Mullins, Russell E Jacobs, Berislav V Zlokovic
Diffuse white-matter disease associated with small-vessel disease and dementia is prevalent in the elderly. The biological mechanisms, however, remain elusive. Using pericyte-deficient mice, magnetic resonance imaging, viral-based tract-tracing, and behavior and tissue analysis, we found that pericyte degeneration disrupted white-matter microcirculation, resulting in an accumulation of toxic blood-derived fibrin(ogen) deposits and blood-flow reductions, which triggered a loss of myelin, axons and oligodendrocytes...
February 5, 2018: Nature Medicine
https://www.readbyqxmd.com/read/29400666/deep-brain-stimulation-of-frontal-lobe-networks-to-treat-alzheimer-s-disease
#20
Douglas W Scharre, Emily Weichart, Dylan Nielson, Jun Zhang, Punit Agrawal, Per B Sederberg, Michael V Knopp, Ali R Rezai
The study objective was to evaluate the safety and efficacy of deep brain stimulation (DBS) at the ventral capsule/ventral striatum (VC/VS) region to specifically modulate frontal lobe behavioral and cognitive networks as a novel treatment approach for Alzheimer's disease (AD) patients. This is a non-randomized phase I prospective open label interventional trial of three subjects with matched comparison groups. AD participants given DBS for at least 18 months at the VC/VS target were compared on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), our primary outcome clinical measure, to matched groups without DBS from the AD Neuroimaging Initiative (ADNI) cohort...
January 30, 2018: Journal of Alzheimer's Disease: JAD
keyword
keyword
83209
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"